Skip to main content
Premium Trial:

Request an Annual Quote

Array Shop HTG Closes $3.4M in Series B Financing Round

NEW YORK, May 4 (GenomeWeb News) - HTG, a gene expression assay-technology company, has closed $3.4 million in a Series B round of private-equity financing, the company said today.

 

The cash brings to $4.6 million in total venture capital HTG has obtained to date.

 

HTG will use the funds to expand manufacturing, sales, and marketing activities; hire additional staff; and increase product trials to support its ArrayPlate qNPA technology.

 

Participating in the financing round were Solstice Capital, Valley Ventures, Emerging Technology Partners, Deimos Ventures, Village Ventures, members of the Tucson Desert Angels, and HTG founder Bruce Seligmann.

 

Solstice Capital, Valley Ventures, and Village Ventures participated in HTG's first round of financing in 2002.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.